MedTrace Logo

Calprotectin for Rapid Diagnostic Infection Spontaneous of Ascites

NCT02857101 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2018-07-18

No results posted yet for this study

Summary

The prognosis of spontaneous bacterial peritonitis (ISLA) remains a serious complication of cirrhosis. Rapid diagnosis of ISLA is a key issue for improving the prognosis. The determination of calprotectin in ascites, used for the diagnosis of infection of ascitic liquid, could allow the diagnosis in a very short time (about 30 minutes). To date, the determination of calprotectin in ascites was not evaluated properly. The investigators would thus evaluate the interest of the determination of calprotectin in ascites for the rapid diagnosis of ISLA in cirrhotic patients, like you, hospitalized for decompensation of their disease. The main purpose of this pilot study will determine the optimal threshold calprotectin in ascites for diagnosis of ISLA.

Conditions

  • Rapid Diagnosis of Spontaneous Infection of Ascitic Fluid

Interventions

OTHER

dosage of calprotectin

Sponsors & Collaborators

  • BÜHLMANN Laboratories

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-02-28
Completion
2019-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02857101 on ClinicalTrials.gov